Navigation Links
Pharmac to Phase Out Aropax, Well-known Antidepressant

Government Drug Agency, Pharmac, is in the process of doing away with a commonly used antidepressant, Aropax. //

Pharmac intends to phase out the ‘Aropax’ brand of paroxetine and bring in the generic alternative ‘Loxamine’. It is estimated that Aropax is used by about 49,000 New Zealanders.

This move has drawn flak from psychiatrists in Australasia. Yet, the agency maintains that both drugs are the same, except for the appearance and the packaging. Further, this move is expected to result in a saving of $45 million over a three year period.

Dr Allen Fraser, chairman of the New Zealand national committee of the Royal Australian and New Zealand College of Psychiatrists, said, "What concerns the college is the insistence in this process that patients currently on paroxetine, the Aropax form, must either pay for it, or be changed to the new form. We had advocated that where the clinician prescribing the medication believed it was in the patient's interest to remain on their current medication, it should remain fully subsidized for those persons. They clearly have not accepted that as a standard. We will still be pursuing that because that's the major issue for us. If patients have been doing well on their current medication, they deserve to still have access to it.”

Pharmac deputy medical director Dr Dilky Rasiah said, "At present, people prescribed paroxetine for the first time need to have previously had a trial of fluoxetine, another antidepressant. Once Loxamine is funded, it will not be subject to this requirement, which will give people easier access to it."

Dr Rasiah said that tests have confirmed the effectiveness of Loxamine brand, at par with Aropax , so patients will not experience any difficulties with change in drug.



'"/>




Page: 1

Related medicine news :

1. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
2. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
3. Medicis Pharmaceutical company enters pediatric market
4. Pharmacies in for a dose of bitter medicine
5. Pharmacia may take 51.5 percent Abbott stake
6. Pharmaceutical companies are targeting patients
7. FDA approves Watson Pharmaceuticals Oxytrol patch
8. Pharmacist’s Role in Medication Error
9. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
10. Indian Pharmaceutical Industries Stops Manufacturing And Sale Of Valdecoxib
11. Pharmaceutical industries grant for R&D to be monitored
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2016)... ... 08, 2016 , ... The Florida Hospital Tampa Wound Healing ... Society (UHMS), the leading authority in hyperbaric medicine. This accreditation identifies the Institute ... and facilities have earned this distinction. This is the second time the Florida ...
(Date:12/8/2016)... PLAINS, N.Y., and JENNERSVILLE, Pa. (PRWEB) , ... ... ... to announce that Penn Medicine Southern Chester County, a Property owned by an ... The $23 million, 72,000 square foot Penn Medicine Southern Chester County ambulatory care ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , ... firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the ... series, and attorneys from the firm’s global Life Sciences & Medical Technology Group have ...
(Date:12/8/2016)... Somerset, N.J. (PRWEB) , ... December 08, 2016 ... ... advanced delivery technologies and development solutions for drugs, biologics and consumer health products, ... The PSCI was set up in 2006 as a non-profit organization to unite ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... as possible. With this in mind, SIGVARIS has created a new line of ... during bed rest and provide the benefits of graduated compression when transitioning from ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)...  Valeant Pharmaceuticals International, Inc. (NYSE: ... positive results from a Phase 3, multicenter double-blind, ... and efficacy of IDP-118 (halobetasol propionate and tazarotene) ... Within the Phase 3 study of ... IDP-118 showed statistical significance to vehicle with a ...
(Date:12/8/2016)... Information products and services provider Elsevier has launched ... largest abstract and citation database of peer-reviewed literature, providing the scholarly ... publishers. The new set of metrics will improve decisions on where ... a journal,s editorial strategy. ... , CiteScore metrics comprise a ...
(Date:12/8/2016)... 2016 Dignitana, a world leader in medical ... Technology, creator of the award-winning, patented Boa® system, to ... the DigniCap® scalp cooling system. DigniCap® was cleared by ... and is the first medical scalp cooling device to ... system features a patented tight-fitting silicone cooling cap that ...
Breaking Medicine Technology: